Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases is a research paper published in Clinical Gastroenterology and Hepatology (2021). On theSindex it has a DataRank of 0. It has been cited 40 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: K23DK117058
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: P30 DK120515
Shire
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5K23DK117058-05
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases
National Institutes of Health
Grant: 5P30DK120515-04
San Diego Digestive Diseases Research Center
National Institutes of Health
Grant: 1Z01BD002019-01
HIV-1 TAT REGULATION OF IL-4 RECEPTORS
FWCI
3.79
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals